INNOVATION

Originator of Entrectinib and other innovative molecules

ABOUT US

Fully integrated platform for R&D value chain

MISSION

“Shaping oncology innovation”. Our commitment.

RESULTS

Proved track record, high quality standards and fully compliant services.

INTELLECTUAL PROPERTY

High value organization for oncology innovation

Delivering innovative drugs and high quality CRO e CDMO services

Mission

The mission of NMS Group is to discover and develop new molecules and therapeutic strategies, contributing to shape the future of cancer care. Thanks to its unique fully integrated R&D chain, the Group is also committed in offering high quality pre-clinical, clinical and production services at a global level.
The vast scientific heritage of internal skills, technology and experience represents our excellence and the basis for achieving our goals with continuous commitment and enthusiasm.

NMS Group is the largest company in Italy committed in innovation and research and development in oncology.

About us

Our company is a high value organization covering the whole R&D process: from pre-clinical phase of research, to First-Time-In-Man of clinical phase, up to production and packaging of the finished drug. Nerviano Medical Sciences represents the innovative heart of the Group and make it an important and international reference in the field of personalized therapy. NMS Group also provides Research and Production services, addressed to local and international markets through three different companies: Accelera, one of the few companies engaged in preclinical research in Italy; Clioss engaged in clinical development starting from First-Time-In-Man and Nerpharma, dealing with activities from formulation to production of the active principle.

Our numbers

About us

 
Licensing
+  
Active patents and
patent applications
+  
Published
papers
+  
People
+  
Pre clinical
studies/year
+  
Overall worldwide collaborations with research & care Centers
 
Production
plants

Media Press & News >

San Diego, 09.07.2019

Trovagene Announces Initiation of Enrollment for Phase 1b/2 Clinical Trial in KRAS-Mutated Colorectal Cancer at Leading Comprehensive Cancer Centers

Trial will evaluate safety and efficacy of onvansertib plus FOLFIRI and Avastin® (bevacizumab) for treatment of patients with KRAS-mutated metastatic. Colorectal Cancer (mCRC). Highly recognized unmet need for 50% of mCRC patients who harbor the KRAS mutation, given current treatment response rate of only 5%. Trovagene to leverage proprietary Precision Cancer Medicine™ tumor genomic technology to assess early indication of treatment response. Trovagene licensed onvansertib (also known as NMS-1286937 and PCM-075) from Nerviano Medical Sciences.
Read more +
Basel, 18.06.2019

Japan becomes the first country to approve Roche’s personalised medicine Rozlytrek (entrectinib)

First tumour-agnostic medicine approved in Japan for adult and paediatric patients with NTRK fusion-positive advanced recurrent solid tumours. Approval supported by the data mainly from the pivotal Phase II STARTRK-2 study showing that Rozlytrek shrank tumours in more than half of people with NTRK fusion-positive solid tumours, across 10 different tumour types, including those with central nervous system metastases. Rozlytrek is also undergoing review in Japan for the treatment of ROS1 fusion-positive non-small cell lung cancer.
Read more +